“OSTEOGROW - Novel Bone Morphogenetic Protein 6-Biocompatible Carrier Device for Bone Regeneration”
Program
FP7 – HEALTH - Collaborative project (Contract Number: 279239)
Duration
54 months (01/01/2012 - 30/06/2016)
Partners from
Croatia, Sweden, Czech Republic, Austria, United Kingdom, Germany, Bosnia and Herzegovina
Project funding
5.683.089,30 €
Project goals
Production, preclinical and clinical testing of the new drug OSTEOGROW for bone regeneration to accelerate healing of bone defects. OSTEOGROW is a new drug (new bone implant) that consists of the autologous carrier of the patient's own blood and biologically active recombinant human protein BMP6 (rhBMP6) with improved properties in bone regeneration compared to currently available options.
Project results
Production of recombinant BMP6 for the purposes of clinical testing of the drug in Phase I/II; Drug testing OSTEOGROW in two Phase I/II clinical studies; Successfully completed international Phase I/II clinical trials in three clinical centres for two indications: i) healing of distal radius fractures (n = 32 patients) and ii) high tibial osteotomy (n = 20).
